Bimekizumab given by vein or by injection in psoriatic arthritis and axial spondyloarthritis
Compares bimekizumab given by vein or injection in adults with active joint disease.
Plain-language title generated from the registry record
Registry title: A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Key facts
- Where
- Albuquerque, Apple Valley, Baytown, Beckley, Bellevue, Chicago, Colleyville, Covina, Duncansville, Fort Collins, Fullerton, Jackson, Lansing, Mesquite, Murfreesboro, Ormond Beach, Peoria, Plano, Riverside, Rock Hill, San Leandro, South Miami, Spokane, Temecula, Upland, Vandalia, West Long Branch, Whittier, and Zephyrhills, United StatesSee the 30 sites
- Phase
- Phase 1
Where in United States
- Pa0019 131Albuquerque, United StatesTaking people
- Pa0019 127Apple Valley, United StatesTaking people
- Pa0019 129Baytown, United StatesTaking people
- Pa0019 130Beckley, United StatesTaking people
- Pa0019 121Bellevue, United StatesTaking people
- Pa0019 132Chicago, United StatesTaking people
- Pa0019 136Colleyville, United StatesTaking people
- Pa0019 111Covina, United StatesTaking people
- Pa0019 115Duncansville, United StatesTaking people
- Pa0019 123Fort Collins, United StatesTaking people
- Pa0019 119Fullerton, United StatesTaking people
- Pa0019 116Jackson, United StatesTaking people
- Pa0019 134Lansing, United StatesTaking people
- Pa0019 135Mesquite, United StatesTaking people
- Pa0019 138Murfreesboro, United StatesTaking people
- Pa0019 143Ormond Beach, United StatesTaking people
- Pa0019 114Peoria, United StatesTaking people
- Pa0019 124Plano, United StatesTaking people
- Pa0019 117Riverside, United StatesTaking people
- Pa0019 142Rock Hill, United StatesTaking people
- Pa0019 125San Leandro, United StatesTaking people
- Pa0019 113South Miami, United StatesTaking people
- Pa0019 145Spokane, United StatesTaking people
- Pa0019 126Temecula, United StatesTaking people
- Pa0019 141Upland, United StatesTaking people
- Pa0019 144Vandalia, United StatesTaking people
- Pa0019 140West Long Branch, United StatesTaking people
- Pa0019 120Whittier, United StatesTaking people
- Pa0019 128Whittier, United StatesTaking people
- Pa0019 133Zephyrhills, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- UCB Biopharma SRL
- Trial code
- NCT07290036
- Record updated
- 6 November 2026
- Original description
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.Read full original descriptionShow less
An Open-label, Randomized, Parallel-group, Noninferiority Study to Evaluate the Pharmacokinetics of Bimekizumab Administered Intravenously or as a Subcutaneous Injection in Participants With Active Psoriatic Arthritis and/or Active Axial Spondyloarthritis
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.
Inclusion: Be 18+ years old and legally able to consent; Have active psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA), suitable for bimekizumab treatment; Weigh between 45-100 kg (females) or 50-100 kg (males); Be biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve or have stopped bDMARDs ≥3 months or 5 half-lives ago.
Exclusion: Recent live vaccines (within 8 weeks) or Bacillus Calmette-Guerin (BCG) (within 1 year); Serious organ system disorders (e.g., heart, liver, kidney, gastrointestinal, neuro); Severe psychiatric issues or substance abuse in the past year; Recent or chronic infections, including tuberculosis (TB) or nontuberculous mycobacterium (NTMB); Other inflammatory diseases (e.g., rheumatoid arthritis (RA), lupus, inflammatory bowel disease (IBD)); Recent use of glucagon-like peptide-1 (GLP-1) agonists (within 28 weeks).